ZEB2 and pancreatic neoplasm: Instead, Fu et al. confirmed that NEAT1 downregulation enhances the sensitivity of gemcitabine-resistant pancreatic cancer cells to gemcitabine via the miR-506-3p/ZEB2/EMT axis [99].